Subscribe
shutterstock_1653845269_taljat_david
Taljat David / Shutterstock.com
4 January 2022AmericasMuireann Bolger

Novartis upholds MS drug patent at Fed Circ

Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya (fingolimod hydrochloride) was valid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More on this story

Americas
Boston Pharma reaches deals with GSK and Novartis
4 October 2018   Boston Pharmaceuticals yesterday signed deals with GSK and Novartis, licensing eight drug candidates in total.
Big Pharma
Fed Circuit reverses Novartis’ drug patent win
23 June 2022   The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.
Biotechnology
Biotech wins $16.5 million in drug royalties dispute
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York